Experiences with

Ipilimumab

Patients received nivolumab (3 mg/kg) and ipilimumab (1 mg/kg) every three weeks for four cycles, followed by maintenance nivolumab therapy. The primary endpoint was the disease control rate exceeding six months.

Mark Linch presented results from the NEPTUNES (NCT03061539), a multi-centre two-cohort, biomarker-selected phase 2 trial evaluating Nivolumab (anti-PD1) and ipilimumab (anti-CTLA4) for metastatic prostate cancer with an immunogenic signature. Dr.

Immunotherapy Here, we report on two patients who received ipilimumab in these trials and are still in long-term complete remission with a follow-up of 64 and 52 months respectively after the initiation of ipilimumab.

Ipilimumab (Yervoy): Ipilimumab is a checkpoint inhibitor that targets CTLA-4 (cytotoxic T-lymphocyte-associated protein 4). It has been investigated in combination with other immunotherapies or with conventional treatments for prostate cancer in clinical trials.

of nivolumab (Opdivo) co-formulated with Halozyme’s proprietary recombinant human hyaluronidase (rHuPH20; subcutaneous nivolumab) for adult patients with solid tumors eligible for previously approved nivolumab indications as monotherapy, monotherapy maintenance following completion of nivolumab plus ipilimumab

An encouraging Opdivo/Yervoy study was presented at ASCO recently, which gave me a little more hope for the future. https://www.onclive.com/view/nivolumab-ipilimumab-bests-nivolumab-in-ovarian-and-extra-renal-clear-cell-carcinomas Yervoy (ipilimumab) is an anti-CTLA-4, which apparently has higher risk

I also found an ongoing trial immunotherapy trial IMPACT (NCT03570619) which combines other drugs used for immunotherapy with CDK12 (ie: Nivolumab and Ipilimumab) Has anyone here in the community had success on either of these trials?

Hi My husband has mesothelioma and has been having immunotherapy (Ipilimumab and Nivolumab) every 3 weeks since early January this year.

The new plan is to combination of dual immunotherapy with two immunotherapy drugs nivolumab and ipilimumab. Has anyone gone through a similar journey when 1st line treatment didn't work and pivoted?

The purpose of the EVOLUTION trial involving 100 patients is to see if combining two drugs ipilimumab and nivolumab, which activate the body's own immune system, with Lu-PSMA can further improve anti-cancer effects of Lu-PSMA.

Yervoy® (ipilimumab), an anti-CTLA-4 (cytotoxic T-lymphocyte-associated antigen 4) monoclonal antibody drug that works to enhance the immune response by targeting a subset of T-cells called Tregs that inhibit the immune response. 5.

He started ipilimumab on November 23rd, 2021. Onco said we will not see fast results like some other drugs like Keytruda and Taf/Mek. A little nerve racking because of course time isn’t on our side. He has a high tumor burden. I would attach some pictures of his arm but it may be too much for some.

Allison M D Anderson and Houston Methodist world leaders in immuno therapy research … check point inhibitors – Ipilimumab (Yervoy) Keytruda etc. before anyone in medicine thought the immune system could kill cancer.

carboplatin, cabazitaxel, nivolumab and ipilimumab combined to slow advanced prostate cancer? Answer: We don't know yet. My PSA numbers have dropped significantly, but I'm very advanced so they dance around a bit. Lower overall but they jump back up at times.

A new treatment for terminal head and neck cancer patients - combining two immunotherapy drugs, nivolumab and ipilimumab. The CheckMate 651 trial, funded by Bristol Myers Squibb - showed especially good results in tumors with high levels of a marker called PD-L1.

Tumor Mutational Burden and Efficacy of Nivolumab Monotherapy and in Combination with Ipilimumab in Small-Cell Lung Cancer. Cancer Cell 2019;35:329. [Crossref] [PubMed] Isaacsson Velho P, Antonarakis ES. PD-1/PD-L1 pathway inhibitors in advanced prostate cancer.

Dr wants to order ipilimumab because it targets different cells than Keytruda was. And that will be the next treatment if this doesn’t work. Still have some things in mind that we will discuss at his appt this upcoming week. He is in so much pain.

It's a hellava long infusion, premeds, nivolumab, ipilimumab, cabazitaxel, and carboplatin - with gaps in between for observation. I had no odd side effects besides a brief 1 minute flush feeling on the back of my neck. Total 7 hours.

Given my prostate has evolved to Gleason 10 and neuroendocrine (small cell) I'm in the process of qualifying for the CHAMP trial: Nivolumab, ipilimumab, cabazitaxel and carboplatin.

I've had my first infusion of the two chemos cabazitaxel and carboplatin and two immuno-therapies (nivolumab and ipilimumab) 14 days ago. My side effects have been less than what docetaxel were.